Soluble Fas ligand expression in the ocular fluids of uveitis patients

References

• Nagata S and Golstein P. The Fas death factor. Science. 1995;267:1449–1456.
   Google Scholar
• Suda T, Takahashi T, Golstein P, and Nagata S. Molecular cloning and expression of the Fas ligand, a novel mem-ber of the tumor necrosis factor family. Cell. 1993;75: 1169–1178.
   Google Scholar
• Gruss HJ and Dower SK. Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. Blood. 1995;85:3378–3404.
   Google Scholar
• Smith CA, Farrah T, and Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell. 1994;76:959–962.
   Google Scholar
• Nagata S and Suda T. Fas and Fas ligand: lpr and gld mutations. Immunol Today. 1995;16:39–43 .
   Web of Science ®Google Scholar
• Rouvier E, Luciani MF, and Golstein P. Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity. J Exp Med. 1993;177:195–200.
   Google Scholar
• Suda T, Okazaki T, Naito Y, Yokota T, Arai N, Ozaki S, Nakao K, and Nagata S. Expression of the Fas ligand in cells of T cell lineage. J Immunol. 1995;154:3806–3813.
   Google Scholar
• Vignaux F, Vivier E, Malissen B, Depraetere V, Nagata S, and Golstein P. TCR/CD3 coupling to Fas-based cy-totoxicity. J Exp Med. 1995;181: 781–786.
   Google Scholar
• Watanabe FR, Brannan CI, Itoh N, Yonehara S, Copeland NG, Jenkins NA, and Nagata S. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J Immunol. 1992;148:1274–1279.
   Google Scholar
• Mohler KM, Sleath PR, Fitzner JN, Cerretti DP, Alderson M, Kerwar SS, Torrance DS, Otten EC, Greenstreet T, Weerawarna K, Kronheim SR, Petersen M, Gerhart M, Kozlosky CJ, March CJ, and Black RA. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature. 1994;370:218–220.
   Google Scholar
• McGeehan GM, Becherer JD, Bast RJ, Boyer CM, Cham-pion B, Connolly KM, Conway JG, Furdon P, Karp S, Kidao S et al. Regulation of tumour necrosis factor-al-pha processing by a metalloproteinase inhibitor. Nature. 1994;370:558–561.
   PubMed Web of Science ®Google Scholar
• Tanaka M, Suda T, Takahashi T, and Nagata S. Expres-sion of the functional soluble form of human fas ligand in activated lymphocytes. Embo J. 1995;14:1129–1135.
   Google Scholar
• Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F, Motoyoshi K, Mizuki M, Tagawa S, Ohga S, Hatake K, Drummond AH, and Nagata S. Fas ligand in human serum. Nat Med. 1996;2:317–322.
   Google Scholar
• Griffith TS, Yu X, Herndon JM, Green DR, and Ferguson TA. CD95-induced apoptosis of lymphocytes in an im-mune privileged site induces immunological tolerance. Immunity. 1996;5:7–16.
   Google Scholar
• Griffith TS, Brunner T, Fletcher SM, Green DR, and Ferguson TA. Fas ligand-induced apoptosis as a mecha-nism of immune privilege. Science. 1995;270:1189–1192.
   Google Scholar
• Hunt JS, Vassmer D, Ferguson TA, and Miller L. Fas ligand is positioned in mouse uterus and placenta to prevent trafficking of activated leukocytes between the mother and the conceptus. J Immunol. 1997;158:4122–4128.
   Google Scholar
• Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, and Duke RC. A role for CD95 ligand in preventing graft rejection. Nature. 1995;377: 630–632.
   Google Scholar
• Stuart PM, Griffith TS, Usui N, Pepose J, Yu X, and Ferguson TA. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J Clin Invest. 1997;99: 396–402.
   Google Scholar
• Bloch ME and Nussenblatt RB. International Uveitis Study Group recommendations for the evaluation of in-traocular inflammatory disease. Am J Ophthalmol. 1987; 103:234–235.
   Google Scholar
• Chan CC, Matteson DM, Li Q, Whitcup SM, and Nussen-blatt RB. Apoptosis in patients with posterior uveitis. Arch Ophthalmol. 1997;115:1559–1567.
   Google Scholar
• Wilson SE, Li Q, Weng J, Barry LP, Jester JV, Liang Q, and Wordinger RJ. The Fas-Fas ligand system and other modulators of apoptosis in the cornea. Invest Ophthalmol Vis Sci. 1996;37:1582–1592.
   PubMed Web of Science ®Google Scholar
• Liles WC, Kiener PA, Ledbetter JA, Aruffo A, and Kleba-noff SJ. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J Exp Med. 1996; 184:429–440.
   Google Scholar
• Tortorella C, Piazzolla G, Spaccavento F, Pece S, Jirillo E, and Antonaci S. Spontaneous and Fas-induced apop-totic cell death in aged neutrophils. J Clin Immunol. 1998;18:321–329.
   Google Scholar
• Suda T, Hashimoto H, Tanaka M, Ochi T, and Nagata S. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the kill-ing. J Exp Med. 1997;186:2045–2050.
   Google Scholar
• Tanaka M, Itai T, Adachi M, and Nagata S. Downregula-tion of Fos ligand by shedding. Nat Med. 1998;4:31–36.
   Google Scholar